Surge In Infectious Disease Fueling The Growth Of The Market Due To Rising Transmission And Need For Timely Detection: Core Growth Enabler in the Rapid Diagnostics Market, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Rapid Diagnostics Industry Market Size Be by 2025?
There has been a swift expansion in the dimensions of the rapid diagnostics market in the past few years. An escalation from $32.01 billion in 2024 to $36.08 billion in 2025 is projected with a compound annual growth rate (CAGR) of 12.7%. Factors such as the growing occurrence of infectious diseases, a surge in point-of-care testing demands, increase in antimicrobial resistance, amplified cognizance concerning early detection of diseases, and heightened healthcare spending in emerging markets have contributed to this growth during the historic period.

What's the Long-Term Growth Forecast for the Rapid Diagnostics Market Size Through 2029?
In the coming years, a considerable acceleration in the expansion of the rapid diagnostics market is anticipated. It's projected to inflate to $57.71 billion by 2029, with a compound annual growth rate (CAGR) of 12.5%. The escalation during the forecasted timeframe can be linked to the increased adoption of personalized medicine, the surge in the incorporation of artificial intelligence in diagnostics, the growing need for home-based testing kits, the hike in healthcare infrastructure investment, and the heightened focus on readiness for pandemics. During the forecasted period, key trends are expected to be the evolution in microfluidics technology, advancement in biosensor-based diagnostics, amalgamation of smartphone applications with diagnostic tools, progress in lab-on-a-chip systems, and innovations in multiplexed testing platforms.

View the full report here:
https://www.thebusinessresearchcompany.com/report/rapid-diagnostics-global-market-report

What Are the Key Growth Drivers Fueling the Rapid Diagnostics Market Expansion?
The growth of the rapid diagnostics market is likely to be spurred on by the escalating incidence of infectious diseases. These diseases stem from various harmful microorganisms such as fungi, parasites, bacteria, and viruses and can spread either directly or indirectly from one individual to another. The surge in infectious diseases can be attributed to an increase in international travel that results in faster transmission and elevated infection rates. Rapid diagnoses of such diseases can greatly assist by providing swift and correct identification of the pathogens, leading to immediate treatment, reduced spread, and better patient outcomes. For example, in May 2025, The World Health Organization (WHO), a specialized agency of the United Nations headquartered in Switzerland that focuses on global public health, stated that since mid-February 2025, there has been a surge in global activity of SARS-CoV-2 (the virus responsible for COVID-19, an infectious disease). Based on information from sentinel sites, the testing positivity rate had escalated to 11%, a figure that was last noted in July 2024. Hence, the surging incidence of infectious diseases is fueling the rapid diagnostics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24679&type=smp

What Are the Key Trends Driving Rapid Diagnostics Market Growth?
Leading firms in the rapid diagnostics market are honing their focus on advancements and innovative solutions such as speedier diagnostic testing tools in a bid to optimize diagnostic precision, cut down on processing times, and enhance patient results in point-of-care contexts. These quick diagnostic testing tools are medical devices engineered to swiftly identify certain illnesses or conditions, usually producing results within minutes at the treatment site. As an illustration, SEKISUI Diagnostics, an American med-tech company, released the OSOM RSV Test in May 2025 - a rapid diagnostic device for the detection of respiratory syncytial virus (RSV). Specifically designed for expert healthcare environments, this test shares its results in as little as 15 minutes. By leveraging a speedy immunochromatographic assay, it discretely identifies RSV nucleoprotein antigen. To support immediate and effective clinical decision-making, the test is utilized with anterior nasal swab samples taken from patients presenting symptoms of a respiratory infection, facilitating a prompt response time.

How Is the Rapid Diagnostics Market Segmented?
The rapid diagnostics market covered in this report is segmented -

1) By Product Type: Kits, Reagents, Instruments, Other Product Types
2) By Platform: Immunoassays, Molecular Detection, Other Rapid Diagnostic Platforms
3) By Application: Blood Glucose Testing, Infectious Disease Testing, Cardiometabolic Testing, Pregnancy and Fertility Testing, Fecal Occult Blood Testing, Coagulation Testing, Toxicology Testing
4) By Distribution Channel: Hospital Pharmacies, Brick and Mortar, E-Commerce, Other Distribution Channels
5) By End Use: Diagnostic Centers, Homecare Settings, Hospital Pharmacies, Other End Users

Subsegments:
1) By Kits: Lateral Flow Assay Kits, PCR Kits, Immunoassay Kits, Microfluidic Kits, Molecular Diagnostic Kits, Multiplex Kits
2) By Reagents: Enzymes, Buffers, Probes and Primers, Stains and Dyes, Antibodies, Calibration and Control Reagents
3) By Instruments: PCR Machines, Lateral Flow Readers, Immunoassay Analyzers, Microfluidic Analyzers, Automated Sample Processors, Biosensors
4) By Other Product Types: Software and Data Management Tools, Sample Collection Devices, Accessories and Consumables, Calibration Standards, Point-of-Care Devices

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24679&type=smp

Which Companies Are Leading the Charge in Rapid Diagnostics Market Innovation?
Major companies operating in the rapid diagnostics market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company, Quest Diagnostics Incorporated, Hologic Inc., bioMérieux S.A., QuidelOrtho Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Cepheid Inc., OraSure Technologies Inc., Nova Biomedical Corporation, Fujirebio Holdings Inc., Sekisui Diagnostics LLC, EKF Diagnostics Holdings plc, Trinity Biotech plc, Abingdon Health plc, Abionic SA

Which Regions Are Leading the Global Rapid Diagnostics Market in Revenue?
North America was the largest region in the rapid diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rapid diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24679

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.